The ethics of CYP2D6 testing for patients considering tamoxifen

Anne Renee Hartman, Paul Helft

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.

Original languageEnglish
Article number103
JournalBreast Cancer Research
Volume9
Issue number2
DOIs
StatePublished - Apr 13 2007

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Ethics
Genes
Genotype
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

The ethics of CYP2D6 testing for patients considering tamoxifen. / Hartman, Anne Renee; Helft, Paul.

In: Breast Cancer Research, Vol. 9, No. 2, 103, 13.04.2007.

Research output: Contribution to journalArticle

@article{5b1c740d3f704fd2bc932eb93da9753d,
title = "The ethics of CYP2D6 testing for patients considering tamoxifen",
abstract = "The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.",
author = "Hartman, {Anne Renee} and Paul Helft",
year = "2007",
month = "4",
day = "13",
doi = "10.1186/bcr1663",
language = "English",
volume = "9",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - The ethics of CYP2D6 testing for patients considering tamoxifen

AU - Hartman, Anne Renee

AU - Helft, Paul

PY - 2007/4/13

Y1 - 2007/4/13

N2 - The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.

AB - The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=34250199706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250199706&partnerID=8YFLogxK

U2 - 10.1186/bcr1663

DO - 10.1186/bcr1663

M3 - Article

C2 - 17433116

AN - SCOPUS:34250199706

VL - 9

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 2

M1 - 103

ER -